Exploring the Economic Viability of Cannabidiol as a Complementary Therapy for Lennox-Gastaut Syndrome
This assessment delves into the cost-effectiveness and budget impact of using cannabidiol (CBD) as an adjunct therapy for patients with Lennox-Gastaut syndrome (LGS). It evaluates the financial implications and potential savings associated with introducing CBD, compared to standard treatment approaches. Through comprehensive analysis, the study shows that CBD not only reduces seizure frequency but also aligns with acceptable economic thresholds, indicating its viability as a therapeutic option. The findings underscore CBD’s promise in improving the quality of life for individuals with LGS while presenting a feasible economic solution for healthcare systems.
